First-in-human Study of Interferon-y PET Imaging to Assess Response to Immunotherapy

Launched by NERISSA T. VIOLA · May 28, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a new imaging technique using a special agent called \[89Zr\]Zr-DFO-emapalumab to see how well immunotherapy works for patients with non-small cell lung cancer (NSCLC). The purpose is to use PET scans, which are detailed imaging tests, to find cancer lesions and check the patient's response to treatment. Participants will have a PET scan before starting immunotherapy and again about 30 days later to compare the results.

To join the study, patients must be at least 18 years old and have a confirmed diagnosis of non-small cell lung cancer, with at least one measurable tumor that is large enough to be seen on a PET scan. They should not have received any immunotherapy for their current cancer stage. Participants will need to complete some health checks before the imaging tests and must be able to stay still during the scans. This study is currently recruiting participants of all genders. If you or someone you know is interested, be sure to discuss it with the healthcare team for more details.

Gender

ALL

Eligibility criteria

• • Inclusion
• • Prior histologic or cytologic diagnosis of non-small cell lung cancer.
• • FDG PET done within 2 months of the baseline imaging, as part of standard-of-care.
• • measurable disease by RECIST 1.1 with at least one lesion of at least 2 cm in a region of the body that can be imaged by PET (e.g.,outside of the liver)
• • must be able to lie still for the tests. Their girth and weight must be suitable to enter the gantry, which varies per tomograph.
• • must be \>18 years old.
• • Patients must sign an informed consent indicating that they are aware of the investigational nature of this study, in keeping with the policies of the cancer center.
• • Physical exam, CBC and Multiphasic (including electrolytes, BUN, creatinine, total bilirubin, AST, and ALT) must be done within 28 days prior to PET imaging
• • Exclusion
• • No prior immunotherapy for current stage of NSCLC (Non Small Cell Lung Cancer). Immunotherapy in neoadjuvant or adjuvant setting and have recurrence at least 12 months following completion of immunotherapy are eligible after discussion with the principle investigator.
• • Pregnant or breast feeding individuals.